Halberd Corp Stock Price, News & Analysis

Halberd Corporation (OTC PINK:HALB) announced a breakthrough in Covid-19 treatment, with a proprietary monoclonal antibody that enhances the effectiveness of a leading commercial Covid-19 antibody from 65% to 94%. This antibody is effective against all current SARS-CoV-2 mutations including Omicron. Their research emphasizes the potential for widespread treatment against evolving variants. CEO William A. Hartman mentions ongoing discussions for potential patents stemming from these promising results, which could attract further industry interest.

Halberd Corporation (OTC PINK:HALB) reported significant technical and organizational milestones for Q2 2022, ending June 30. The company added animal testing expertise to enhance its patented process for removing disease antigens. A scientific article is in review for patent protection, while outreach for endorsements from the NFL and NCAA is ongoing. Halberd is exploring FDA authorization for its technology and submitted audited financials to the SEC for OTCQB uplisting. Future plans include animal testing and potential spin-offs of specialized subsidiaries, broadening treatment options for various diseases.

Halberd Corporation (OTC PINK:HALB) has announced the formation of a specialized subgroup to focus on cancer treatment leveraging its patented extracorporeal treatment approach. This new division will operate alongside ongoing efforts in neurodegenerative diseases. The company aims to develop three significant cancer antibodies (PD-1, BTLA, CTLA-4) and anticipates potential spin-off opportunities for shareholders. The CEO highlighted that this initiative may enhance both treatment efficacy and shareholder value without compromising existing projects.

Halberd Corporation (OTC PINK:HALB) has signed a non-disclosure agreement with Mississippi State University to conduct animal testing aimed at obtaining FDA certification for its disease eradication technology. Following proof-of-concept success in eliminating antigens linked to neurodegenerative diseases, this step is crucial for the development of effective treatments. The company aims to optimize research resources while preparing for clinical trials. Leadership expresses eagerness to engage with testing experts to refine processes for potential FDA approval.

Halberd Corporation (OTC PINK:HALB) has developed a protocol that effectively reduces specific harmful cytokines in blood or cerebral spinal fluid. Researchers achieved an 80% reduction of Interleukin-4 (IL-4) in vitro, exceeding the target of 75%, within approximately five minutes using a chromatography method. This breakthrough allows doctors to finely tune disease-causing elements, potentially transforming treatments for conditions like severe depression, PTSD, and cancer. The company focuses on eliminating pathogens from blood serum and aims for FDA certification in future studies.

Halberd Corporation (OTC PINK:HALB) has contracted mdi Consultants, Inc. to help navigate the FDA’s application process for its patented technologies. With 44 years of experience and over 4,000 successful FDA submissions, mdi aims to expedite Halberd's journey toward certification. Halberd acknowledges its lack of FDA expertise and believes that mdi's guidance will substantially improve its chances of success. The company has secured exclusive rights to three patents and filed 20 related applications since its restructuring in April 2020.

Halberd Corporation (OTC PINK:HALB) has submitted its fully audited financials and Form-10 to the SEC, marking a pivotal step towards up-listing from OTC-PINK to OTCQB. This transition requires adherence to GAAP standards and timely SEC filings. CEO William Hartman emphasized this move enhances the company's credibility, attracting investor confidence. Halberd is advancing its patented technology, which targets neurological diseases, through upcoming laboratory and human clinical trials. The company is also exploring partnerships with larger firms to expedite its development timeline.

Halberd Corporation (OTC PINK:HALB) announced Dr. W. Gregg Sturrus, a member of its research team, delivered a TEDx Talk on their patented method for eliminating neurodegenerative disease proteins using lasers and nanoparticles. The presentation outlines the technology's history and its potential applications in treating various diseases. Halberd holds exclusive rights to three issued patents and has filed numerous related applications to boost shareholder value. For updates, interested parties are encouraged to subscribe for news.

Halberd Corporation (OTC PINK:HALB) reported significant advancements in Q1 2022, including the elimination of key antigens related to neurodegenerative diseases and successful tests demonstrating its proprietary Covid-19 antibody's efficacy against multiple variants. The company has strengthened its advisory team with experts in microbiology and infectious diseases. Looking ahead, Halberd aims to enhance animal testing, publish research, and explore partnerships with pharmaceutical companies. Financial audits are complete, awaiting regulatory filings. Halberd emphasizes its commitment to transparency and innovation in disease treatment.